NO920671D0 - Fremgangsmaate for aktivering av rekombinante proteiner - Google Patents

Fremgangsmaate for aktivering av rekombinante proteiner

Info

Publication number: NO920671D0
Authority: NO; Norway
Prior art keywords: recombinant proteins; procedure; amino acids; activating recombinant; activating
Prior art date: 1991-02-21

Application number

NO920671A

Other languages

English (en)

Other versions

NO920671L (no

NO300329B1 (no

Inventor

Dorothea Ambrosius

Carola Dony

Rainer Rudolph

Original Assignee

Boehringer Mannheim Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-02-21

Filing date

1992-02-20

Publication date

1992-02-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6425597&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO920671(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1992-02-20 Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh

1992-02-20 Publication of NO920671D0 publication Critical patent/NO920671D0/no

1992-08-24 Publication of NO920671L publication Critical patent/NO920671L/no

1997-05-12 Publication of NO300329B1 publication Critical patent/NO300329B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
- C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Analytical Chemistry (AREA)
General Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Toxicology (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Plant Pathology (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Crystallography & Structural Chemistry (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Dental Preparations (AREA)
Manufacture Of Macromolecular Shaped Articles (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO920671A 1991-02-21 1992-02-20 Fremgangsmåte for aktivering av rekombinante proteiner NO300329B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE4105480A DE4105480A1 (de)	1991-02-21	1991-02-21	Verbesserte aktivierung von rekombinanten proteinen

Publications (3)

Publication Number	Publication Date
NO920671D0 true NO920671D0 (no)	1992-02-20
NO920671L NO920671L (no)	1992-08-24
NO300329B1 NO300329B1 (no)	1997-05-12

Family

ID=6425597

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO920671A NO300329B1 (no)	1991-02-21	1992-02-20	Fremgangsmåte for aktivering av rekombinante proteiner

Country Status (20)

Country	Link
US (1)	US5578710A (no)
EP (1)	EP0500108B1 (no)
JP (1)	JP2528232B2 (no)
KR (1)	KR950014493B1 (no)
AT (1)	ATE144284T1 (no)
AU (1)	AU641081B2 (no)
CA (1)	CA2061569C (no)
CZ (1)	CZ282744B6 (no)
DE (2)	DE4105480A1 (no)
DK (1)	DK0500108T3 (no)
ES (1)	ES2093122T3 (no)
FI (1)	FI106029B (no)
GR (1)	GR3021395T3 (no)
HU (1)	HU214881B (no)
IE (1)	IE920276A1 (no)
IL (1)	IL101024A (no)
MX (1)	MX9200709A (no)
NO (1)	NO300329B1 (no)
NZ (1)	NZ241570A (no)
ZA (1)	ZA921230B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5718893A (en) *	1984-04-15	1998-02-17	Foster; Preston F.	Use of G-CSF to reduce acute rejection
US5581476A (en)	1993-01-28	1996-12-03	Amgen Inc.	Computer-based methods and articles of manufacture for preparing G-CSF analogs
SE9301057L (sv) *	1993-03-30	1994-10-01	Pharmacia Ab	Beredning med kontrollerad frisättning
US5536495A (en) *	1994-04-15	1996-07-16	Foster; Preston F.	Use of G-CSF to reduce acute rejection
US20030053982A1 (en)	1994-09-26	2003-03-20	Kinstler Olaf B.	N-terminally chemically modified protein compositions and methods
US5824784A (en)	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
US6245740B1 (en)	1998-12-23	2001-06-12	Amgen Inc.	Polyol:oil suspensions for the sustained release of proteins
ES2276822T3 (es)	2000-09-08	2007-07-01	Massachusetts Institute Of Technology	Metodos y composiciones con analogos del g-csf.
ES2309167T3 (es)	2001-02-19	2008-12-16	Merck Patent Gmbh	Metodo para identificar epitotes de celulas t y metodo para preparar moleculas con inmunogenicidad reducida.
BR0211071A (pt)	2001-07-11	2004-12-21	Maxygen Holdings Ltd	Conjugado polipeptìdico apresentando atividade de g-csf, método para preparar um conjugado de g-csf, composição, método para tratar um mamìfero sofrendo de um nìvel neutrofìlico insuficiente, e, uso do conjugado polipeptìdico
EP1490402A4 (en)	2002-03-20	2007-05-02	Biopolymed Inc	PREPARATION OF CYSTEINREST STOCHIOMETRIC WITH BIOKOMPATIBLE POLYMER CONJUGATED G-CSF
US7666627B2 (en) *	2002-08-08	2010-02-23	Targetex Kft.	Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
US7785601B2 (en)	2002-12-31	2010-08-31	Sygnis Bioscience Gmbh & Co. Kg	Methods of treating neurological conditions with hematopoietic growth factors
US7695723B2 (en)	2002-12-31	2010-04-13	Sygnis Bioscience Gmbh & Co. Kg	Methods of treating neurological conditions with hematopoietic growth factors
US7220407B2 (en)	2003-10-27	2007-05-22	Amgen Inc.	G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
EP1817047B1 (en)	2004-11-05	2012-02-08	Northwestern University	Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders
JP5137821B2 (ja)	2005-06-01	2013-02-06	マキシジェン，インコーポレイテッド	Ｐｅｇ化されたｇ−ｃｓｆポリペプチドおよびその製造方法
AR064235A1 (es) *	2006-07-24	2009-03-25	Tetralogic Pharmaceuticals Cor	Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer
US20090324609A1 (en)	2007-08-09	2009-12-31	Genzyme Corporation	Method of treating autoimmune disease with mesenchymal stem cells
US8758761B2 (en)	2007-09-30	2014-06-24	University Of Florida Research Foundation, Inc.	Combination therapies for treating type 1 diabetes
US8283372B2 (en)	2009-07-02	2012-10-09	Tetralogic Pharmaceuticals Corp.	2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
RU2573909C2 (ru)	2010-03-04	2016-01-27	Пфенекс Инк.	Способ получения растворимого рекомбинантного белка интерферона без денатурирования
PL2547699T3 (pl)	2010-03-17	2017-04-28	Ratiopharm Gmbh	Sposób otrzymywania biologicznie czynnego rekombinowanego ludzkiego g-csf
EP2552949B1 (en)	2010-04-01	2016-08-17	Pfenex Inc.	Methods for g-csf production in a pseudomonas host cell
CA2876099A1 (en) *	2012-08-02	2014-02-06	F. Hoffmann-La Roche Ag	Method for producing monomeric and multimeric molecules and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4532207A (en) *	1982-03-19	1985-07-30	G. D. Searle & Co.	Process for the preparation of polypeptides utilizing a charged amino acid polymer and exopeptidase
DK55685A (da) *	1985-02-07	1986-08-08	Nordisk Gentofte	Enzym eller enzymkompleks med proteolytisk aktivitet
US4530787A (en) *	1984-03-28	1985-07-23	Cetus Corporation	Controlled oxidation of microbially produced cysteine-containing proteins
US5082775A (en) *	1984-05-11	1992-01-21	Berlex Laboratories, Inc.	Efficient process for isolating insoluble heterologous protein using non-ionic detergents
US4948729A (en) *	1985-03-25	1990-08-14	Cetus Corporation	Production of soluble recombinant proteins
US4783415A (en) *	1985-03-28	1988-11-08	Meiji Seika Kabushiki Kaisha	Gene coding for signal peptides and utilization thereof
US5087564A (en) *	1985-06-20	1992-02-11	Monsanto Company	Release of recombinant peptides from polypeptides using V8 endopeptidase
DE3636903A1 (de) *	1985-12-21	1987-07-02	Hoechst Ag	Fusionsproteine mit eukaryotischem ballastanteil
JPH0618781B2 (ja) *	1986-10-18	1994-03-16	中外製薬株式会社	感染症治療剤
US5013653A (en) *	1987-03-20	1991-05-07	Creative Biomolecules, Inc.	Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
ATE113985T1 (de) *	1987-03-20	1994-11-15	Creative Biomolecules Inc	Verfahren zur reinigung von rekombinanten polypeptiden.
JPH03503596A (ja) *	1987-06-24	1991-08-15	ノボ・ノルディスク　エー／エス	蛋白質若しくはポリペプチドの調製方法、該ポリペプチドをコードするｄｎａ配列、該ｄｎａ配列およびポリペプチドを有する微生物および該ポリペプチドの薬学的製剤としての利用
DE3835350A1 (de) *	1988-10-17	1990-04-19	Boehringer Mannheim Gmbh	Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern
ZA901719B (en) *	1989-03-19	1991-01-30	Akzo Nv	Hog cholera virus vaccine and diagnostics
US5191063A (en) *	1989-05-02	1993-03-02	University Of Medicine And Dentistry Of New Jersey	Production of biologically active polypeptides by treatment with an exogenous peptide sequence
US5115102A (en) *	1989-07-21	1992-05-19	Monsanto Company	Variant proteins and polypeptides possessing enhanced affinity for immobilized-metal affinity matrices
EP0545999B1 (en) *	1990-08-20	1997-06-04	Novo Nordisk A/S	Process for the preparation of biologically active IGF-1 using IGF-1 having an amino-terminal extension

1991
- 1991-02-21 DE DE4105480A patent/DE4105480A1/de not_active Withdrawn
1992
- 1992-01-28 IE IE027692A patent/IE920276A1/en not_active IP Right Cessation
- 1992-02-10 NZ NZ241570A patent/NZ241570A/en not_active IP Right Cessation
- 1992-02-14 AU AU10948/92A patent/AU641081B2/en not_active Ceased
- 1992-02-20 CA CA002061569A patent/CA2061569C/en not_active Expired - Fee Related
- 1992-02-20 MX MX9200709A patent/MX9200709A/es not_active IP Right Cessation
- 1992-02-20 DE DE59207351T patent/DE59207351D1/de not_active Revoked
- 1992-02-20 HU HU9200548A patent/HU214881B/hu not_active IP Right Cessation
- 1992-02-20 CZ CS92499A patent/CZ282744B6/cs not_active IP Right Cessation
- 1992-02-20 EP EP92102864A patent/EP0500108B1/de not_active Revoked
- 1992-02-20 DK DK92102864.3T patent/DK0500108T3/da active
- 1992-02-20 AT AT92102864T patent/ATE144284T1/de not_active IP Right Cessation
- 1992-02-20 NO NO920671A patent/NO300329B1/no unknown
- 1992-02-20 FI FI920742A patent/FI106029B/fi not_active IP Right Cessation
- 1992-02-20 JP JP4033257A patent/JP2528232B2/ja not_active Expired - Lifetime
- 1992-02-20 IL IL10102492A patent/IL101024A/en not_active IP Right Cessation
- 1992-02-20 ES ES92102864T patent/ES2093122T3/es not_active Expired - Lifetime
- 1992-02-20 ZA ZA921230A patent/ZA921230B/xx unknown
- 1992-02-21 KR KR1019920002697A patent/KR950014493B1/ko not_active Expired - Fee Related
1993
- 1993-10-21 US US08/139,054 patent/US5578710A/en not_active Expired - Lifetime
1996
- 1996-10-17 GR GR960402469T patent/GR3021395T3/el unknown

Also Published As

Publication number	Publication date
NO920671L (no)	1992-08-24
JP2528232B2 (ja)	1996-08-28
FI106029B (fi)	2000-11-15
CA2061569A1 (en)	1992-08-22
NO300329B1 (no)	1997-05-12
KR920016464A (ko)	1992-09-24
HU214881B (hu)	1998-07-28
US5578710A (en)	1996-11-26
FI920742L (fi)	1992-08-22
ES2093122T3 (es)	1996-12-16
HU9200548D0 (en)	1992-04-28
DK0500108T3 (da)	1997-03-24
MX9200709A (es)	1992-09-01
ATE144284T1 (de)	1996-11-15
EP0500108A3 (en)	1993-04-07
ZA921230B (en)	1992-11-25
EP0500108B1 (de)	1996-10-16
DE4105480A1 (de)	1992-08-27
EP0500108A2 (de)	1992-08-26
HUT68021A (en)	1995-04-04
AU1094892A (en)	1992-08-27
IL101024A (en)	1996-06-18
IL101024A0 (en)	1992-11-15
JPH05244977A (ja)	1993-09-24
AU641081B2 (en)	1993-09-09
IE920276A1 (en)	1992-08-26
CZ282744B6 (cs)	1997-09-17
DE59207351D1 (de)	1996-11-21
GR3021395T3 (en)	1997-01-31
NZ241570A (en)	1994-09-27
KR950014493B1 (ko)	1995-12-02
CA2061569C (en)	2000-10-24
CS49992A3 (en)	1992-09-16
FI920742A0 (fi)	1992-02-20

Publication	Publication Date	Title
NO920671D0 (no)	1992-02-20	Fremgangsmaate for aktivering av rekombinante proteiner
DE69033040D1 (de)	1999-05-12	Verfahren zur Herstellung von biologisch aktivem Protein (z.B. TGF)
DK0535091T3 (da)	1996-05-06	Knogleinducerende farmaceutiske formuleringer
ES2120964T3 (es)	1998-11-16	Peptidos osteogenicos.
ATE339878T1 (de)	2003-12-15	Myc-bindende zinkfinger-proteine, ihre herstellung und ihre verwendung
DE59101580D1 (de)	1994-06-09	Trägergebundene rekombinante proteine, verfahren zur herstellung und verwendung als immunogene und vakzine.
DE3688324D1 (de)	1993-05-27	Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel.
ES2124247T3 (es)	1999-02-01	Conjugado de calcitonina y de polietilenglicol.
DE68907635D1 (de)	1993-08-26	Loetmaterial fuer brillengestelle und brillengestelle, bei denen dieses loetmaterial verwendet ist.
ATE255638T1 (de)	2003-12-15	Nukleotidsequenzen und gegen cycloheximid resistente proteine
EP0537981A3 (de)	1994-10-12	Verfahren zur Spaltung von Acylthiohydantoinen und Anwendung davon zur C-terminalen Peptidsequenzierung.
FR2635527B1 (fr)	1992-06-12	Il2 humaine recombinante non glycosylee sous forme reduite, son procede d'obtention et son application comme medicament
SE9602822D0 (sv)	1996-07-19	New receptor
DE68910771D1 (de)	1993-12-23	Verfahren zur Herstellung von verbessertem Proteinhydrolysat.
ATE86974T1 (de)	1993-04-15	(2-cyan-2-oximinoacetyl)-aminosaeure-derivate.
DE59109235D1 (de)	2002-05-29	Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung
IT8719551A0 (it)	1987-03-03	Plasmidi ricombinanti utili perl'espressione in bacillus di proteine eterologhe.
DE58909208D1 (de)	1995-06-08	Verfahren zur Herstellung von Imidazol-2-carbonsäuren.
DE59208025D1 (de)	1997-03-20	Neue thrombininhibitorische proteine aus landblutegeln
DE69534738D1 (de)	2006-04-06	Leukocyten-aktivierender Faktor
ATE87906T1 (de)	1993-04-15	(2-cyan-2-oximinoacetyl)-aminosaeure-derivate.
DE58909261D1 (de)	1995-06-29	Ancrod-proteine, ihre herstellung und verwendung.
MX9205978A (es)	1993-04-01	Nuevas proteinas inhibidoras de trombina de garrapatas.
DE58906628D1 (de)	1994-02-17	Neue Bisester ungesättigter Carbonsäuren, ihre Herstellung und Verwendung in härtbaren Gemischen.
ATE76081T1 (de)	1992-05-15	Verfahren zur herstellung von dipeptiden mit nterminalen nichtproteinogenen aminosaeuren.